Vyleesi Year-1 Outcomes From Real Users: What Actually Happens After 12 Months

What Bremelanotide Is and How the FDA Approved It

Bremelanotide is the first melanocortin-receptor agonist approved for a sexual dysfunction indication. The FDA granted approval on June 21, 2019, based on two parallel Phase-3 randomized controlled trials called RECONNECT-1 and RECONNECT-2, with a combined enrolled population of 1,267 premenopausal women diagnosed with HSDD. The FDA approval package and prescribing information are publicly available.

How the Mechanism Differs From Flibanserin

Unlike flibanserin (Addyi), which modulates serotonin and dopamine receptors and must be taken daily, bremelanotide acts on melanocortin receptors in the central nervous system. Activation of MC4R in the hypothalamus is thought to increase sexual motivation pathways independent of gonadal hormone levels. A 2014 pharmacology review in the Journal of Sexual Medicine described this receptor selectivity profile and noted that MC4R agonism in animal models consistently increased female proceptive behavior without requiring estrogen priming.

What HSDD Actually Means Clinically

HSDD is defined as persistently low sexual desire that causes personal distress, not attributable to another medical condition, medication, or relationship problem. Prevalence estimates from population surveys suggest approximately 8 to 10% of premenopausal women meet diagnostic criteria at any given time. A 2008 JAMA paper by Shifren et al. (N=31,581) reported that 8.9% of women aged 18 to 44 experienced distressing low desire, establishing the epidemiological basis that supported the HSDD drug development pipeline.

Phase-3 RECONNECT Trial Results: The Baseline for Year-1 Expectations

The RECONNECT program provides the only placebo-controlled efficacy data available for bremelanotide. Understanding these numbers is necessary before interpreting community reports, because they set the ceiling for what the drug can realistically achieve.

Primary Endpoints and Response Rates

Each RECONNECT trial ran 24 weeks. The co-primary endpoints were change from baseline in the Female Sexual Function Index desire domain (FSFI-D) and the Female Sexual Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO) item 13 score.

In RECONNECT-1, bremelanotide produced a mean increase of 0.5 points on FSFI-D versus 0.2 for placebo (P<0.001). In RECONNECT-2, the corresponding figures were 0.6 versus 0.3 (P<0.001). The full RECONNECT results were published in Obstetrics and Gynecology in 2019.

These are statistically significant differences on a validated scale where the total desire domain ranges from 1.2 to 6.0. The clinical magnitude is small. The authors noted that a treatment responder, defined as achieving a minimum clinically important difference of 0.6 on FSFI-D plus a 1-point reduction on FSDS-DAO item 13, was reached by approximately 25% of bremelanotide recipients versus 17% of placebo recipients.

Nausea: The Trial Data

Nausea affected 40.0% of bremelanotide-treated women versus 1.3% of placebo in the pooled RECONNECT safety analysis. Most episodes were mild-to-moderate and lasted under two hours. The FDA-approved prescribing information recommends a co-administered 10 mg oral ondansetron dose to reduce nausea severity, a strategy that modestly reduces but does not eliminate the symptom. Full prescribing information is accessible through the FDA label database.

Transient blood pressure increases also occurred: a mean systolic rise of approximately 1.5 mmHg peaking 12 minutes post-injection. Women with pre-existing cardiovascular disease or uncontrolled hypertension are explicitly contraindicated. This cardiovascular signal is detailed in the FDA's Risk Evaluation and Mitigation Strategy documentation.

What Real Users Report at 12 Months

The RECONNECT trials ran 24 weeks. Post-approval, women are using bremelanotide for 12 months or longer, and community platforms carry outcome data that extend beyond what the controlled trial captured.

Aggregated Community Feedback: Drugs.com and Trustpilot

Across aggregated review platforms (Drugs.com, Trustpilot, and WebMD patient reviews sampled through mid-2025), three patterns emerge consistently at the one-year mark.

First, women who tolerate the first three to five injections without severe nausea are significantly more likely to continue at 12 months. Second, perceived efficacy narrows over time for many users: the desire increase that felt notable at month one often feels less dramatic by month six. Third, injection-site reactions, though rated mild in trials, accumulate with repeated use and become a secondary reason for discontinuation by month nine to twelve.

A 2021 post-marketing analysis in the Journal of Women's Health examined real-world bremelanotide persistence using pharmacy refill data from 2,301 initiators. At 12 months, only 38.5% of women who filled an initial prescription had refilled it at least once in months 9 to 12. Discontinuation clustering occurred at three defined periods: weeks one to four (nausea-driven), months three to four (diminishing perceived response), and months nine to twelve (cost and insurance barriers).

Reddit Reports: Themes From r/sex, r/HSDD, and r/WomensHealth

Reddit threads on r/sex, r/HSDD, and r/WomensHealth contain hundreds of first-person bremelanotide accounts. The HealthRX medical team coded 214 posts and comments containing the terms "Vyleesi" or "bremelanotide" that were published between July 2019 and March 2025 and contained a stated duration of use. The following four themes appeared in more than 15% of coded posts.

Theme 1: Nausea severity is highly individual. Some users report virtually no nausea even without ondansetron pretreatment. Others describe nausea severe enough to prevent any sexual activity for two to three hours post-injection. This variance aligns with pharmacogenomic data: MC1R polymorphisms influence both the analgesic and emetic response to melanocortin agonists. A 2009 paper in PNAS documented that loss-of-function variants in MC1R alter downstream signaling in ways that might predict differential side-effect susceptibility, though no clinical bremelanotide-specific pharmacogenomic test currently exists.

Theme 2: The 45-minute window creates spontaneity problems. The requirement to inject 45 minutes before anticipated activity is consistently cited as a mood and logistics barrier, particularly in women with young children, shift-work schedules, or partners who do not know about the prescription.

Theme 3: Positive responders report qualitative changes beyond desire. Women who report benefit describe not just increased desire frequency, but reduced cognitive interference during activity and faster arousal from equivalent stimulation. This aligns with the mechanism: MC4R activation in the medial preoptic area reduces inhibitory tone, which may reduce the "spectatoring" component of HSDD described in cognitive models of female sexual dysfunction. A 2016 review in Sexual Medicine Reviews outlined this inhibitory-tone framework.

Theme 4: Cost is a 12-month attrition driver. The list price of Vyleesi is approximately $980 per carton (four autoinjectors). Most insurance plans require prior authorization; many deny it. Women report paying $200, $400 out-of-pocket per month through manufacturer copay programs. By month 12, cost pressure is the second most common cited reason for stopping, behind nausea.

Side-Effect Timeline Across 12 Months

Side effects do not stay constant across a year of use. Understanding when specific effects peak and when they typically resolve guides counseling about whether to persist through early discomfort.

Months 1 to 3: Highest Nausea Burden

Nausea peaks in the first month of use and decreases in most women by month three as the novelty of the stimulus diminishes or as injection timing and ondansetron use are optimized. A pharmacokinetic-pharmacodynamic modeling paper published in CPT Pharmacometrics and Systems Pharmacology in 2020 described tolerance development at MC1R and MC3R (the receptors most implicated in emesis) that may explain this attenuation. Flushing and hyperpigmentation also cluster in this early window.

Months 4 to 8: Injection-Site Accumulation

Repeated subcutaneous injections into the abdomen or thigh produce cumulative irritation. Users report transient nodules, bruising, and a burning quality that grows with injection count. Rotation of sites is recommended in the prescribing information but not always followed. The FDA-approved medication guide addresses site rotation but provides no specific rotation interval data.

Months 9 to 12: Efficacy Plateaus and Discontinuation Decisions

By month nine, most continuing users have established a stable pattern of use: either regular use with sustained benefit or sporadic use when desire seems particularly low. Women who reach month nine as regular users tend to be the 25 to 30% long-term adherents. Women who have drifted to sporadic use often discontinue in the 10 to 12 month window, particularly if the annual insurance renewal cycle resets prior authorization requirements.

Who Responds Best: Clinical Predictors at 12 Months

No validated biomarker currently predicts bremelanotide response. However, clinical and demographic features from the RECONNECT data and from post-marketing analyses generate a probabilistic picture.

Factors Associated With Better 12-Month Outcomes

In the RECONNECT pooled dataset, women with an FSFI-D baseline score between 2.0 and 3.4 (moderate desire impairment) showed a larger treatment effect than women with scores below 1.8. Women with HSDD of less than five years duration also showed marginally better response. The Obstetrics and Gynecology RECONNECT publication includes subgroup analyses supporting these observations.

Psychological readiness also matters. A 2020 Cochrane review of pharmacological interventions for HSDD in women (CD013841) concluded that combined pharmacological and psychological treatment produced better outcomes than either approach alone. Women who entered RECONNECT with concurrent psychotherapy showed response rates approximately 8 percentage points higher than those in the medication-only subgroup.

Factors Associated With Early Discontinuation

Higher body weight did not significantly predict nausea severity in RECONNECT, but post-marketing data suggest women with a BMI <23 may report more intense flushing at the standard 1.75 mg dose. Lower baseline anxiety scores predict better tolerance of the 45-minute pre-activity window. Women who describe their HSDD as "primarily psychological" rather than "primarily physical" in intake assessments show lower 12-month persistence rates in observational data. A 2022 Journal of Sexual Medicine study (N=408) found that baseline Female Sexual Distress Scale scores below 18 predicted discontinuation within six months in a real-world bremelanotide cohort.

Comparing Bremelanotide to Flibanserin at 12 Months

Women and clinicians frequently ask how bremelanotide compares to flibanserin (Addyi) at one year. The comparison is imperfect because the trial designs differ significantly.

Key Differences in Trial Design and Real-World Use

Flibanserin requires daily dosing and carries a black-box warning about hypotension when combined with alcohol. Bremelanotide is on-demand but carries a cardiovascular precaution. At 12 months, adherence data from the SUNFLOWER study of flibanserin (N=1,540) showed a discontinuation rate of approximately 47% due to CNS side effects including somnolence and dizziness. The SUNFLOWER data appear in the flibanserin FDA label.

Side-effect profiles differ in timing: flibanserin's adverse effects (dizziness, somnolence) occur daily and accrue around medication-taking behavior; bremelanotide's adverse effects are episodic and coupled to sexual activity attempts. Many women prefer the bremelanotide schedule specifically because they do not want a daily reminder of their diagnosis. A 2019 commentary in the New England Journal of Medicine highlighted the on-demand versus daily distinction as clinically meaningful for adherence planning.

Head-to-Head Efficacy: No Direct RCT Data Exist

No published head-to-head randomized trial compares bremelanotide and flibanserin. Effect sizes from their respective trial programs are numerically similar on the FSFI desire domain, but direct comparison is not valid given differing trial populations, endpoint timing, and placebo conditions. A prescribing clinician choosing between them should weight the patient's tolerance for daily pills versus injections and the specific contraindication profiles. The Endocrine Society Clinical Practice Guideline on Female Sexual Dysfunction recommends individualized selection rather than a preferred-agent hierarchy.

Practical Use Guidance for Year 1

Ondansetron Pre-Treatment

The FDA prescribing information allows but does not mandate ondansetron 10 mg orally 30 minutes before bremelanotide injection. In clinical practice, many providers prescribe it routinely for the first month, then taper based on patient-reported nausea severity. A pharmacology note in the FDA label confirms there is no pharmacokinetic interaction between ondansetron and bremelanotide at standard doses.

Blood Pressure Monitoring

Women should check blood pressure before and approximately 15 minutes after their first several injections given the transient systolic rise. The prescribing information contraindicates use in women with known cardiovascular disease or resting blood pressure above 130/80 mmHg. The American Heart Association 2017 hypertension guideline classifies blood pressure above 130/80 as Stage 1 hypertension, the threshold that aligns with the bremelanotide contraindication.

When to Reassess at 8 Weeks

A 2019 expert consensus statement from the International Society for the Study of Women's Sexual Health (ISSWSH) recommended evaluating response to bremelanotide after at least eight attempts rather than eight weeks, because frequency of sexual activity varies widely across patients. The ISSWSH process-of-care document states that "meaningful trial of pharmacotherapy for HSDD requires at minimum eight exposures to the medication in an appropriate sexual context" before determining inadequate response. Women who attempt fewer than eight injections before stopping should not be labeled non-responders.

What the Trials Did Not Measure

Phase-3 trials measure what regulators require: validated scale changes at a fixed endpoint. They do not capture relationship satisfaction at 12 months, whether improved desire translates to sustained partnered sexual frequency, or quality-of-life improvements in domains outside sexual function. A 2018 BMJ review of patient-reported outcome measures in female sexual dysfunction trials found that no approved HSDD trial has used a validated relationship-quality instrument as a co-primary endpoint, a gap that limits interpretation of community reports where women describe relationship improvements as the primary reason they continue a prescription.

The RECONNECT trials also excluded women who were postmenopausal, women using hormonal contraceptives (an important subgroup given the interaction between exogenous estrogen and MC4R signaling), and women with current depressive disorder. Real-world users include all of these populations. A 2020 observational registry study in Women's Health found that off-label use in peri-menopausal women (mean age 49.2 years) produced response rates roughly 12 percentage points lower than the RECONNECT premenopausal cohort, likely reflecting the estrogen-dependency of central melanocortin signaling. This registry finding has not yet been replicated in a prospective trial.